Loading
A patient with a rare cancer treated at a small hospital should have their case reviewed by the national experts by video before treatment starts. Make that referral automatic.
Outcomes for sarcoma, rare gynaecological tumours, and other uncommon cancers depend heavily on expert review before surgery, yet patients at smaller hospitals are often treated locally without it. National virtual multidisciplinary boards, with mandatory pre-treatment referral for a defined list of diagnoses and a turnaround guarantee, have been implemented for sarcoma in several countries. Extending the model with a legal or reimbursement mandate would standardise access.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.